Ionis Pharmaceuticals IONS Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.06B+47.5% | $943.71M+33.8% | $966.96M+20.4% | $944.05M+16.1% | $717.25M-7.6% | ||
| $17.43M+65.5% | $15.91M+41.8% | $11.78M+12.8% | $10.52M-9.1% | $10.53M+5.9% | ||
| $1.04B+47.3% | $927.8M+33.7% | $955.17M+20.5% | $933.54M+16.4% | $706.72M-7.8% | ||
| 98.4%-0.2pp | 98.3%-0.1pp | 98.8%+0.1pp | 98.9%+0.3pp | 98.5%-0.2pp | ||
| —— | $915.62M+1.6% | $912.1M+1.2% | $908.57M+0.9% | $905.05M+0.6% | ||
| $467.98M+60.8% | $393.87M+47.3% | $351.76M+40.5% | $316.59M+22.4% | $291.08M+21.4% | ||
| $1.41B+18.6% | $1.33B+12.3% | $1.25B+6.1% | $1.21B+2.7% | $1.19B+2.1% | ||
| -$352.25M+25.4% | -$381.69M+19.7% | -$278.05M+24.9% | -$266.52M+27.0% | -$472.43M-21.4% | ||
| -33.3%+32.6pp | -40.4%+26.9pp | -28.8%+17.4pp | -28.2%+16.6pp | -65.9%-15.8pp | ||
| $18.31M+8.0% | $17.26M+1.6% | $16.63M-4.2% | $16.57M-4.8% | $16.95M+11.5% | ||
| -$16.28M-1,172% | -$15.36M-1,254% | $1.23M-2.8% | $1.01M-71.7% | $1.52M-89.3% | ||
| -$325.09M+30.0% | -$379.6M+17.5% | -$258.72M+27.3% | -$274.43M+22.1% | -$464.16M-27.6% | ||
| $1.89M+131% | $1.79M+129% | -$2.38M-179% | -$6.22M-147% | -$6.13M-129% | ||
| -$326.98M+28.6% | -$381.39M+16.0% | -$256.34M+28.6% | -$268.22M+26.7% | -$458.03M-19.0% | ||
| -30.9%+33.0pp | -40.4%+24.0pp | -26.5%+18.2pp | -28.4%+16.6pp | -63.9%-14.3pp | ||
| -$2.07+30.8% | -$2.44+19.7% | -$1.69+30.7% | -$1.84+27.0% | -$2.99-12.0% | ||
| -$338.65M+26.5% | -$369.24M+20.3% | -$266.8M+39.4% | -$255.17M+32.8% | -$460.85M-14.6% | ||
| -32%+32.2pp | -39.1%+26.6pp | -27.6%+27.2pp | -27%+19.7pp | -64.3%-12.5pp | ||
| -$352.25M+25.4% | -$381.69M+19.7% | -$278.05M+38.6% | -$266.52M+32.1% | -$472.43M-13.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Ionis Pharmaceuticals's revenue?
- Ionis Pharmaceuticals (IONS) generated $1.1B in revenue over the trailing twelve months, up 47.5% year over year.
- Is Ionis Pharmaceuticals profitable?
- Ionis Pharmaceuticals is not currently profitable: it reported a net loss of $327.0M over the trailing twelve months, a -30.9% net margin.
- What are Ionis Pharmaceuticals's profit margins?
- Gross margin is 98.4% and operating margin is -33.3%, with a -30.9% net margin.
- What is Ionis Pharmaceuticals's earnings per share?
- Ionis Pharmaceuticals's diluted EPS over the trailing twelve months is $-2.07.
- Where does Ionis Pharmaceuticals's income statement data come from?
- Every line is extracted from Ionis Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
